Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Berberine in diabetic nephropathy: mechanistic overview
Yang Yanru1, Cui Jia1, Yu Yan2
1Gansu University of Chinese Medicine, Lanzhou, 730000 People's Republic of China.
Berberine (BBR) shows promise for diabetic nephropathy (DN) by targeting multiple pathways. This natural compound alleviates inflammation, oxidative stress, and fibrosis, offering a potential new treatment for metabolic kidney disease.
Area of Science:
- Nephrology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD).
- Current treatments for DN are insufficient to halt disease progression.
- Novel therapeutic interventions are urgently needed for DN management.
Purpose of the Study:
- To review the complex pathogenesis of diabetic nephropathy (DN).
- To evaluate the therapeutic potential of berberine (BBR) for DN.
- To analyze the molecular, cellular, and epigenetic mechanisms of BBR action in DN.
Main Methods:
- Comprehensive literature review.
- Analysis of molecular pathways involved in DN pathogenesis.
- Evaluation of berberine's effects on cellular and epigenetic mechanisms.
Main Results:
- Berberine (BBR) protects kidneys through multiple mechanisms.
- BBR activates AMPK, inhibits NF-κB and TGF-β/Smad3 signaling, and upregulates Nrf2.
- BBR preserves podocyte function, modulates metabolism, and influences epigenetic processes.
Conclusions:
- Berberine (BBR) is a promising multi-target therapeutic agent for diabetic nephropathy (DN).
- BBR may offer superior efficacy compared to single-pathway treatments.
- BBR provides a scientific rationale for treating metabolic kidney diseases.
More Related Videos
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Diuretics
Oral Hypoglycemic Agents: Biguanides and Glitazones
Antihypertensive Drugs: Potassium-Sparing Diuretics